

# Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/GE3013BB56BEN.html>

Date: March 2018

Pages: 47

Price: US\$ 3,500.00 (Single User License)

ID: GE3013BB56BEN

## Abstracts

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H1 2018

### SUMMARY

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H1 2018, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.

The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ophthalmology which include indications Amyotrophic

Lateral Sclerosis, Parkinson's Disease, Brain Ischemia, Neurodegenerative Diseases and Retinal Degeneration.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Overview

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Treeway BV

UniQure NV

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

- Drug Profiles

AMT-090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-812 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAUR-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smilagenin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TW-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)  
- Dormant Products

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)  
- Product Development Milestones

Featured News & Press Releases

Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association

Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy

Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane

Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane

Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis

Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease

Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis

Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic

## Lateral Sclerosis Study

Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis

Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status

Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease

Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane

Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease

Jan 21, 2008: Phytopharm Announces \$1.16 million Funding For Cogane

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by GlaxoSmithKline Plc, H1 2018  
Pipeline by Treeway BV, H1 2018  
Pipeline by UniQure NV, H1 2018  
Dormant Projects, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

GlaxoSmithKline Plc

Treeway BV

UniQure NV



## I would like to order

Product name: Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/GE3013BB56BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE3013BB56BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

